Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Doxazosin mesilate
Teva UK Ltd
C02CA04
Doxazosin mesilate
4mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050400; GTIN: 5017007014713
IF YOU TAKE MORE DOXAZOSIN THAN YOU SHOULD If you have taken more than the dosage prescribed or if you think a child or someone else has swallowed any of the tablets, contact your nearest hospital casualty department or your doctor immediately. An overdose is likely to cause low blood pressure, which may make you feel dizzy or faint. In case of serious dizziness or imminent fainting you should lie down immediately with your head downward. Please take this leaflet, any remaining tablets and the container with you to the hospital or doctor so that they know which tablets were consumed. IF YOU FORGET TO TAKE DOXAZOSIN If you forget to take a tablet, leave that dose out completely. Then go back to your usual schedule. Do not take a double dose to make up for a forgotten dose. Take the remaining doses at the correct time. In case of doubt you should always consult your pharmacist or doctor. IF YOU STOP TAKING DOXAZOSIN You should continue to take these tablets for as long as your doctor tells you to. If the use of this medication is suddenly stopped, the symptoms that existed before the start of the treatment may reoccur. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. POSSIBLE SIDE EFFECTS Like all medicines, this medicine can cause side effects, although not everybody gets them. STOP TAKING THE TABLETS AND TELL YOUR DOCTOR IMMEDIATELY or go to the casualty department at your nearest hospital if you experience any of the following effects: • allergic reactions, this can be recognized by e.g. rash and/or itch • swelling of the face due to fluid accumulation (facial oedema). These are very serious but uncommon side effects. You may need urgent medical attention or hospitalisation. COMMON (may affect up to 1 in 10 people) • infection of the respiratory tract • infection of the urinary tract • headache • dizziness • sleepiness • low blood pressure (hypotension), faintness or dizziness caused by low blood pressure when getting up from a sitting or lying positio Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Doxazosin 4 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 4.85 mg doxazosin mesilate equivalent to 4 mg of doxazosin Excipient(s) with known effect Each tablet contains 80.0 mg lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet 4 mg: white oblong scored tablet, “D4” engraved on one side The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Essential hypertension. Symptomatic treatment of benign prostatic hyperplasia (BPH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The duration of therapy will be decided by the physician. HYPERTENSION: The usual dosage limits of doxazosin lie between 1 and 8 mg per day. The maximum recommended dosage is 16 mg per day. The initial dosage is 1 mg, to be taken before retiring to bed. This dose is maintained for 1 or 2 weeks. The dose can then be increased to 2 mg once a day for another 1 or 2 weeks. If necessary the daily dose can then be gradually increased, observing equal intervals, to 4, 8 and 16 mg once a day, depending on the patient's response. The maximum daily dose should not exceed 16mg BENIGN PROSTATE HYPERPLASIA: The initial dose of doxazosin is 1 mg (1 mg tablet) on the 1st to 8th day once daily and 2 mg (2 mg tablet) on the 9th to 14th day. Subsequently, dose should be titrated individually to 4 mg and to the maximum recommended dosage of 8 mg, depending on the urodynamic parameters and the BPH symptomatology of the patient. The recommended titration interval is 1 to 2 weeks. The usual recommended dose is 2-4 mg daily. Doxazosin is administered once a day. If the doxazosin treatment has been stopped for a number of days, the regimen should be determined again. RENAL IMPAIRMENT Because the pharmacokinetics of doxazosin remain unchanged in patients with renal insufficiency, and no evidence exists that doxazosin will exacerbate Read the complete document